Jeevan Scientific Technology Reports Strong Growth in FY26

Revenue from operations reached Rs 61.54 crore on a consolidated basis for FY26, up from Rs 46.84 crore in FY25. Net profit after tax surged to Rs 1.03 crore, compared to Rs 0.06 crore in the previous fiscal year.

Reader Takeaway: Robust operational growth and USFDA clearance support performance, while minor regulatory fines remain inconsequential for shareholders.

What just happened

Jeevan Scientific Technology (JSTL) has filed its audited financial results for the year ended March 31, 2026. The company saw significant year-over-year growth across both standalone and consolidated metrics. Standalone net profit rose to Rs 1.65 crore, with earnings per share (EPS) increasing to Rs 0.83.

Why this matters

The company’s focus on its core clinical research business is yielding results. The addition of six new LC-MS/MS systems brings their total fleet to 17 instruments, significantly enhancing capacity for bio-analytical studies. Furthermore, the successful completion of a USFDA inspection serves as a major quality validation for their clinical facility.

Governance and Updates

The company has scheduled its Annual General Meeting for September 25, 2026. Board resolutions include the re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director and the continuation of Mr. Nageswar Rao Yarllagadda in his leadership role. The company also confirmed that no adverse remarks or fraud reports were issued by statutory auditors.

Compliance and Capital

JSTL disclosed a minor fine of Rs 2,360 levied by the BSE for a one-day procedural delay regarding the Stakeholders' Relationship Committee composition, which has been rectified. Regarding capital deployment, the company has utilized Rs 10.84 crore of the Rs 30.74 crore raised through preferential allotment for capital expenditure and working capital requirements.